Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Epstein

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Blood|September 20, 2014
Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myelomaStephen W Erickson, Vinay R Raj, Owen W Stephens, et al.
Blood|May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Blood|February 6, 2014
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk diseaseJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|May 7, 2015
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myelomaJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Blood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.
Stem Cells (Dayton, Ohio)|July 7, 2011
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li, Wen Ling, Angela Pennisi, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Blood|September 20, 2014
Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myelomaStephen W Erickson, Vinay R Raj, Owen W Stephens, et al.
Blood|May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyYang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Blood|February 6, 2014
Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk diseaseJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|May 7, 2015
Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myelomaJeffrey R Sawyer, Erming Tian, Christoph J Heuck, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Blood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.
Stem Cells (Dayton, Ohio)|July 7, 2011
Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in boneXin Li, Wen Ling, Angela Pennisi, et al.
American Journal of Hematology|April 7, 2017
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition diseaseMeera Mohan, Amy Buros, Pankaj Mathur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan TransplantsYogesh S Jethava, Alan Mitchell, Joshua Epstein, et al.
Pageof 9